Controlled drug delivery approaches for rheumatoid arthritis

Journal of Applied Pharmaceutical Science

Volumn 2, Issue 8, 2012, Pages 21-32

  Kaur, Amandeep ^a   Harikumar, S L ^a  

^a INSTITUTE OF NANO SCIENCE AND TECHNOLOGY   (India)

Author keywords

Controlled delivery; Delivery of disease modifying antirheumatic drugs; Delivery of NSAIDs; DMARDs; Inflammatory disease; Rheumatoid arthritis

Indexed keywords

EID: 84876123119     PISSN: None     EISSN: 22313354     Source Type: Journal    
DOI: 10.7324/JAPS.2012.2803     Document Type: Article

References (106)

1. Adeyeye CM., Price JC. Chemical, Dissolution Stability and Microscopic Evaluation of Suspensions of Ibuprofen and Sustained Release Ibuprofen-Wax Microspheres. Informa Healthcare. 2005; 14(3): 357-377.
2. Afeltra A. Treatment of Rheumatoid Arthritis: New Therapeutic Approaches with Biological Agents. Journal of Rheumatology. 2001; 1(1):45-65.
3. Ahmed IS, Nafadi MM, Fatahalla FA. Formulation of a Fast-Dissolving Ketoprofen Tablet Using Freeze-Drying in Blisters Technique. Informa Healthcare. 2000; 32(4): 437-442.
4. Alan M., Agustin, M, David RM, Harris HM, David B, Peng LZ, Christopher RL, Barry J G, Sean C. A Randomized, Controlled, Clinical Trial of Etoricoxib in the Treatment of Rheumatoid Arthritis. The Journal of Rheumatology. 2002; 29(8):1623-1630.
5. Alexandros A. Abatacept: A Biologic Immune Modulator for Rheumatoid Arthritis. Informa Healthcare. 2011. 11(8): 1113-1129.
6. Alexander D., Maurizio B, Stefano C, Wolfgang B, Neil W, Giovanni G, Walter R. Economic Evaluation of Tocilizumab Combination in the Treatment of Moderate-to-Severe Rheumatoid Arthritis in Italy. Informa Healthcare. 2012; 3(5):434-435.
7. Albin P., Markus A, Pelah Z, Ben-Zvi Z. Slow-Release Indomethacin Formulations Based On Polysaccharides. Journal of Controlled Release. 2004; 29(2): 25-39.
8. Amita A., Bharat BA. Natural Products as a Gold Mine for Arthritis Treatment. Current Opinion in Pharmacology. 2010; 7(3): 344-351.
9. Anne SV., Veronika B, Nicholas M. The Potential of Liposomal Drug Delivery for the Treatment of Inflammatory Arthritis. The Journal of Rheumatology. 2002; 12(4): 182-196.
10. Arica B., Calis P, Atilla NT, Durlu N, Cakar HSK, Hincal AA. In Vitro and in Vivo Studies of Ibuprofen-loaded Biodegradable Alginate Beads. Informa Healthcare. 2005; 22(2):153-165.
11. Ariel G., Saltan S, Juha N. Comparison of a slow-release Indomethacin tablet and naproxen in osteoarthritis. Informa Healthcare. 2001; 9(7): 500-504.
12. Arias J., Lopez-Viota M, Lopez-Viota J, Delgado AV. Development of Iron/Ethyl Cellulose (Core/Shell) Nanoparticles Loaded With Diclofenac Sodium for Arthritis Treatment. International Journal of Pharmaceutics. 2009; 382(1): 270-276.
13. Ashok RC., Prasad V. Transdermal Delivery of Methotrexate using Mixed Grades of Eudragit: Physico-Chemical, In-Vitro, and In-Vivo Evaluations. Informa Healthcare. 2001; 25(2): 53-72.
14. Ayhan S., Yalcin O, Askin I. Preparation and in Vitro Evaluation of Sustained Release Tablet Formulations of Diclofenac Sodium. Current Therapeutic Research. 2005; 60(2): 171-177.
15. Babar A., Bellete T, Plakogiannis FM. Ketoprofen Suppository Dosage Forms: In Vitro Release and in Vivo Absorption Studies in Rabbits. Informa Healthcare. 2009; 25(2): 241-245.
16. Barbara S., Nelson LR, Ketan P. Tumor Necrosis Factor (TNF) Inhibitor Therapy for Rheumatoid Arthritis, Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontology. Medical Management and Pharmacology Update. 2008; 106(6): 778-787.
17. Barbara L., Federica B, Vittorio Z, Teresa C. Gastro Resistant Microcapsules: New Approaches for Site-Specific Delivery of Ketoprofen. Informa Healthcare. 2009; 16(1): 24-29.
18. Baumgartner H., Schwarz HA, Blum W, Bruhin A, Gallachi G, Goldinger G, Saxer M, Trost H. Ibuprofen and Diclofenac Sodium in the Treatment of Osteoarthritis: A Comparative Trial of two Once-Daily Sustained-Release NSAID Formulations. Informa Healthcare. 2009; 13(8): 435-444.
19. Brabander CD., Vervaet C, Gortz JP, Remon, JP, Berlo JA. Bioavailability of Ibuprofen from Matrix Mini-Tablets Based on a Mixture of Starch and Microcrystalline Wax. International Journal of Pharmaceutics. 2000; 2(4):81-8631.
20. Beom K., Myoung W, Kang ML, Cheo SK. In Vitro Permeation Studies of Nanoemulsions Containing Ketoprofen as a Model Drug. Informa Healthcare. 2008; 15(7): 465-469.
21. Bernard G., Petra E. Comparative Clinical Trial with Immediate-Release Diclofenac Pellets. Current Therapeutic Research. 2003; 54(2):152-160.
22. Biju SS., Saisivam S, Maria NS, Rajan G, Mishra PR. Dual Coated Erodible Microcapsules for Modified Release of Diclofenac Sodium. European Journal of Pharmaceutics and Biopharmaceutics. 2008; 58(1): 61-67.
23. Chon WJ., Josephson MA. Leflunomide in renal transplantation. Expert Review of Clinical Immunology. 2001; 7(3): 273-281.
24. Cheng L. Diclofenac Sodium Controlled Release Matrix Tablets. Journal of Pharmacy and Pharmacology. 2005; 15(5): 360-364.
25. Chenjie Y., Paul DR. Immunosuppressive Exosomes: A New Approach for Treating Arthritis. International Journal of Rheumatology. 2012; 3(1): 129-131.
26. Christine TN. Nanotherapeutic Approaches for the Treatment of Rheumatoid Arthritis. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology. 2011; 3(6): 607-619.
27. Choudhury PK., Panigrahi TK, Murthy PN, Tripathy NK, Behera S, Panigrahi R. Novel Approaches and Developments in Colon Specific Drug Delivery Systems. Webmed Central Pharmaceutical Sciences. 2012; 3(2):341-344.
28. Chilukuri SR., Lakshm MR. Spectrophotometric Determination of Azathioprine in Pharmaceutical Formulations, Talanta. 2008; 47(5): 1279-1286.
29. Claudia V., Marlies W, Jurgen H. Evaluation of Novel Soya-Lecithin Formulations for Dermal Use Containing Ketoprofen as a Model Drug. Journal of Controlled Release. 2008; 63(2): 165-173.
30. Conner CS. Oral gold in arthritis. South African Journal of Arthritis & Rheumatism. 2009; 18(10): 804-805.
31. Comoglu T., Gonul N, Baykara T. The Effects of Pressure and Direct Compression on Tabletting of Microsponges. International Journal of Pharmaceutics. 2002; 242(2): 191-195.
32. Crawford B., Brazier J, Strand V, Doyle J. Treatment with Leflunomide Improves the Utility of Patients with Active Rheumatoid Arthritis. Journal of Value in Health. 2001; 4(2): 70-71.
33. Crowley B., Hamill J, Lyndon S, McKellian JF, Williams P, Miller AJ. Controlled-Release Indomethacin and Sustained-Release Diclofenac Sodium in the Treatment of Rheumatoid Arthritis: A Comparative Controlled Clinical Trial. Informa Healthcare. 2001; 12(3):143-150.
34. Emel OC., Nurcan B, Evren A, In Vitro Studies on Controlled-Release Cellulose Acetate Films for Local Delivery of Chlorhexidine, Indomethacin and Meloxicam. Journal of Clinical Periodontology. 2004; 31(12):1117-1121.
35. Erin D., Jeffrey MW. Etanercept: A Therapeutic Approach to Rheumatoid Arthritis. Informa Healthcare. 2008; 8(4): 491-502.
36. Fernandes L., Jenkins R. Investigation into the Duration of Action of Sustained-Release Ibuprofen in Osteoarthritis and Rheumatoid Arthritis. Informa Healthcare. 2004; (13)4: 242-250.
37. Gohel MC., Amin AF. Formulation Design and Optimization of Modified-Release Microspheres of Diclofenac Sodium. Informa Healthcare. 2009; 25(2): 247-251.
38. Gostick N., James IG, Khong TK, Roy P, Shepherd PR, Miller AJ. Controlled-Release Indomethacin and Sustained-Release Diclofenac Sodium in the Treatment of Osteoarthritis: A Comparative Controlled Clinical Trial in General Practice. Informa Healthcare. 2007; 12(3): 135-142.
39. Hasan MM., Najibt NM, Muti HY. A Pharmacokinetic Study on two Sustained-Release Formulations of Indomethacin in Normal Subjects Following a Single Dose Administration. Journal of Clinical Pharmacy and Therapeutics. 2009; 19(5): 295-299.
40. Huabing C., Xueling C, Danrong D, Jin L, Huibi X, Xiang-liang Y. Microemulsion-Based Hydrogel Formulation of Ibuprofen for Topical Delivery. International Journal of Pharmaceutics. 2006; 315(2): 52-58.
41. Hofkens W., Hoven JM, Pesman GJ, Nabbe KC, Sweep FC, Storm G, Berg WB, Lent PL. Safety of Gluco-Corticoids can be improved By Dosages of Liposomal Steroid Formulations in Murine Antigen-Induced Arthritis: Comparison of Prednisolone with Budesonide. International Journal of Pharmaceutics. 2006; 416(2):493-498.
42. Jager E., Campos MM, Morrone JB, Calixt AR, Pohlmann SS. Effects of Indomethacin-loaded Nanocapsules in Experimental Models of Inflammation. British Journal of Pharmacology. Informa Healthcare. 2009; 158(4): 1104-1111.
43. Janjikhel RK., Adeyeye CM. Stereospecific Formulation and Characterization of Sustained Release Ibuprofen Microspheres. Informa Healthcare. 2009; 14(4):409-426.
44. Joseph I., Venkataram S. Indomethacin Sustained Release from Alginate-Gelatin or Pectin-Gelatin Coacervate. International Journal of Pharmaceutics. 2009; 126(2): 161-168.
45. Jundt JW., Browne BA, Fiocco GP, Steele AD. A Comparison of Low Dose Methotrexate Bioavailability: Oral Solution, Oral Tablet, Subcutaneous and Intramuscular Dosing. Journal of Rheumatology. 2003; 20(11): 1845-9.
46. Jung M., Kim J, Kim M, Alhalaweh A, Cho W, Hwang S, Velaga SP. Bioavailability of Indomethacin-Saccharin Co Crystals. Journal of Pharmacy and Pharmacology. 2010; 62(11): 1560-1568.
47. Kamel AH., Sokar MS, Al Gamal SS, Naggar VF. Preparation and Evaluation of Ketoprofen Floating Oral Delivery System. International Journal of Pharmaceutics. 2001; 220(2): 13-21.
48. Kavitha D., Naga SJ, Shanker P. Pharmacosomes: An Emerging Vesicular System. International Journal of Pharmaceutical Sciences Review and Research. 2010; 5(3): 168-171.
49. Katare OP., Vyas SP, Dixit, VK. Enhanced In Vivo Performance of Liposomal Indomethacin Derived from Effervescent Granule Based Proniosomes. Informa Healthcare. 2005; 12(5): 487-493.
50. Kennedy AC., Mullen BJ, Roth SH, Germain BF, Boner RA, Wei N, Willkens RF, Lawson JG, Appelrouth DJ, White RE. A Double-Blind Comparison of the Efficacy and Safety of Ketoprofen Extended-Release (200 Mg Once Daily) and Diclofenac (75 Mg Twice Daily) for Treatment of Osteoarthritis. Current Therapeutic Research. 2009; 55(2): 119-132.
51. Kirwan JR. Combination Therapy Including Glucocorticoids: The New Gold Standard for Early Treatment in Rheumatoid Arthritis. Ann Intern Med. 2012; 156(5):390-391.
52. Khosro A., Yousef J, Siavoush D, Ghobad M, Fatemeh KN. Naproxen-Eudragit Nanoparticles: Preparation and Physicochemical Characterization, Journal of Rheumatology. 2011; 83(1): 155-159.
53. Kramar A., Turk S, Vrecer F. Statistical Optimization of Diclofenac Sustained Release Pellets Coated with Polymethacrylicfilms. International Journal of Pharmaceutics. 2003; 256(1):43-52.
54. Landewe RB., Goei HS. A Randomized, Double-Blind, 24-Week Controlled Study of Low-Dose Cyclosporine versus Chloroquine for Early Rheumatoid Arthritis. Arthritis Rheum. 2003; 37(4): 637.
55. Lanza FL., Marathi UK, Anand BS, Lichtenberger LM. Clinical Trial: Comparison of Ibuprofen-Phosphatidylcholine and Ibuprofen on the Gastrointestinal Safety and Analgesic Efficacy in Osteoarthritic Patients. Alimentary Pharmacology & Therapeutics. 2008; 28(4): 431-442.
56. Lewis L., Boni R, Adeyeye CM. Effect of Emulsifier Blend on the Characteristics of Sustained Release Diclofenac Microspheres. Informa Healthcare. 2008; 15(3): 283-298.
57. Li SP., Feld KM, Kowarski CR. Preparation of a Controlled Release Drug Delivery System of Indomethacin, Informa Healthcare. 2004; 20(7):1121-1145.
58. Lydia GS., Jaap F, Pilar B, Piet LC, Van R. Methotrexate in Combination with Sulfasalazine is more effective in Rheumatoid Arthritis Patients. Journal of Rheumatology. 2008; 48: 828-833.
59. Manadan A., Augustinz S. The Treatment of Psoriatic Arthritis. American Journal of Therapeutics. 2006; 13(1): 72-79.
60. Manconi M., Mura S, Sinico C, Fadda AM, Molina F. Development and Characterization of Liposomes Containing Glycols as Carriers for Diclofenac, Colloids and Surfaces: Physicochemical and Engineering Aspects. Informa Healthcare. 2009; 342(3): 53-58.
61. Mathew ST., Devi SG, Vinod B. Formulation and in Vitro-in Vivo Evaluation of Ketoprofen-Loaded Albumin Microspheres for Intramuscular Administration. Informa Healthcare. 2009; 26(5): 456-469.
62. Maria L., Gonzalez R, Francesca M, Paola M, Antonio MR. In Vitro Release of Sodium Diclofenac from a Central Core Matrix Tablet Aimed for Colonic Drug Delivery. European Journal of Pharmaceutical Sciences. 2003; 20(1): 125-131.84.
63. Meyers OL., Klemp P. An Oral Formulation of Gold for the Treatment of Rheumatoid Arthritis. South African Medical Journal. 2003; 59(27): 969-971.
64. Mikuls TR., Weaver AL. Lessons Learned in the use of Tumor Necrosis Factor-Alpha Inhibitors in the Treatment of Rheumatoid Arthritis. Current Rheumatology Reports. 2003; 5(4): 270-277.
65. Morley KD., Bernstein RM, Hughes GR, Black CM, Rajapakse CN., Wilson L. A Comparative Trial of a Controlled-Release Formulation of Ketoprofen and a Conventional Capsule Formulation of Ketoprofen in Patients with Osteoarthritis of the Hip. Informa Healthcare. 2004; 9(1): 28-34.
66. Muhammad JH., Roland M. Development of Controlled Release Formulations of Ketoprofen for Oral Use. Informa Healthcare. 2005; 21(12): 1463-1472.
67. Muhammad RI., Ishtiaq A, Mohiuddin AQ, Habibur R. Once Daily Sustained-Release Matrix Tablet of Naproxen: Formulation and in Vitro Evaluation. Journal of Pharmaceutical Sciences. 2010; 9(1):1816-1820.
68. Paola B., Eleonora A, Luisa V, Stefano A, Adriana M. Diclofenac Sodium Multisource Prolonged Release Tablets-a Comparative Study on the Dissolution Profiles, Journal of Pharmaceutical and Biomedical Analysis. 2005; 37(4): 679-685.
69. Pandit SS., Hase DP, Bankar MM, Patil AT, Gaikwad NJ. Ketoprofen-Loaded Eudragit RSPO Microspheres: An Influence of Sodium Carbonate on in Vitro Drug Release and Surface Topology. Informa Healthcare. 2001; 26(3): 195-201.
70. Peeyush B., Himanshu C, Deepti C, Prajapati SK, Singh S. Formulation and in-Vitro Evaluation of Floating Microballoons of Indomethacin. Acta Pharmaceutical Drug Research. 2010; 67(3): 291-298.
71. Peppercorn MA. Sulfasalazine Pharmacology, Clinical Use, Toxicity. Ann Intern Med. 2004; 101(3): 377-386.
72. Pharm CT. Nano Therapeutic Approaches for the Treatment of Rheumatoid Arthritis. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2011; 3(1):109-110.
73. Phillips NC., Thomas DP, Knight CG, Dingle JT. Liposome-Incorporated Corticosteroids, Therapeutic Activity in Experimental Arthritis. Annals of the Rheumatic Diseases. 2001; 38(6): 234-237.
74. Prasanthi NL., Murthy, GK. Design and Development of Controlled Release Diclofenac Sodium Capsules. International Journal of Advances in Pharmaceutical Sciences. 2010; 1(3): 59-65.
75. Puebla P., Pastoriza P, Barcia E, Fernandez-Carballido A. PEG-Derivative Effectively Modifies The Characteristics of Indomethacin-PLGA Microspheres Destined to Intra-Articular Administration. Informa Healthcare. 2005; 22(7): 793-808.
76. Rabindranath P., Bort MC, Debnath R, Gupta BK. In Vitro-In Vivo Correlation Study of Leflunomide Loaded Microspheres. International Journal of Pharmacy and Pharmaceutical Sciences. 2009; 1(1): 165-170.
77. Rhymer AR., Hart CB, Daurio C. Double-Blind Trial Comparing Indomethacin Sustained Release Capsules with Indomethacin Capsules in Patients with Rheumatoid Arthritis. The Journal of Rheumatology. 2002; 21 (2): 101-106.
78. Rodrigues MR., Lanzarini CM, Ricci-Junior E. Preparation, In Vitro Characterization and in Vivo Release of Naproxen Loaded in Poly-Caprolactone Nanoparticles. Informa Healthcare. 2006; 16(1): 12-21.
79. Roland B., Chen H. Indomethacin Polymeric Nanosuspensions prepared by Microfluidization. Journal of Controlled Release. 2006; 12(3): 223-233.
80. Roland WM. Sustained-Release Indomethacin in the Comprehensive Management of Osteoarthritis. The American Journal of Medicine. 2000; 79(4): 3-23.
81. Rosemary HM. The Role of Nutrition and Diet in Rheumatoid Arthritis. Proceedings of the Nutrition Society. 2009; 57(1): 231-234 .113.
82. Rowe WL., Goodwin AP, Miller AJ. The Efficacy of Pre-Operative Controlled-Release Indomethacin in the treatment of PostOperative Pain. Informa Healthcare. 2000; 12(10): 662-667.
83. Rojkovich B., Hodinka L, Balint G, Szegedi G, Varju T, Tamasi L, Molnar M, Szilagyi L, Szocsik K. Cyclosporin and Sulfasalazine Combination in the Treatment of Early Rheumatoid Arthritis. Informa Healthcare., 2009; 28(4): 216-22.
84. Rossum V. Sulfasalazine in the Treatment of Juvenile Chronic Arthritis: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study. Arth Rheum. 2004; 41: 808-816.
85. Ryley NJ. Lingam GA. Pharmacokinetic Comparison of Controlled-Release and Standard Naproxen Tablets. Informa Healthcare. 1999; 11(1): 10-15.
86. Ryley NJ., Corey P, Willans M, Percy JS, Russell AS, Bellamy N, Fitzgerald A. Clinical Evaluation of a New Controlled-Release Formulation of Naproxen in Osteoarthritis and Rheumatoid Arthritis. Informa Healthcare. 2008; 11(1): 16-27.
87. Sajeev C., Vinay R, Archna RN. Oral Controlled Release Formulation of Diclofenac Sodium by Microencapsulation with Ethyl Cellulose. Informa Healthcare. 2002; 19(6): 753-760.
88. Semalty A., Semalty M, Singh D, Rawat MS. Development and Characterization of Aspirin-Phospholipid Complex for Improved Drug Delivery. International Journal of Pharmaceutical Sciences and Nanotechnology. 2010; 3(20):940-947.
89. Saravanan M., Anbu J, Maharajan G, Pillai KS. Targeted Delivery of Diclofenac Sodium via Gelatin Magnetic Microspheres Formulated for Intra-Arterial Administration. Informa Healthcare. 2008; 16(5): 366-378.
90. Schorn DS. An Oral Gold Formulation in Rheumatoid Arthritis. S Afr Med J. 2000; 62(10): 313-6.
91. Schumacher HR., Chen LX. Injectable Corticosteroids in Treatment of Arthritis of the Knee. The American Journal of Medicine. 2005; 118(11):1208-1214.
92. Schattenkirchner M. Long-Term Safety of Ketoprofen in an Elderly Population of Arthritic Patients. Informa Healthcare. 2008; 20(1): 27-36.
93. Singh S., Gajra B, Rawat M, Muthu MS. Enhanced Transdermal Delivery of Ketoprofen from Bioadhesive Gels. Pak. J. Pharm. Sci. 2005; 22(2): 193-198.
94. Silson J. Use of Sustain Release Formulation in Rheumatoid Arthritis and Osteoarthritis. Journal of Clinical Pharmacology. 2000, 7(2):97-107.
95. Tak P., Parnham, MJ. New Therapeutic Targets in Rheumatoid Arthritis. Journal of Rheumatology. 2003; 14(6): 608-609.
96. Tuncay M., Calis S, Kas HS, Ercan MT, Peksoy I. In Vitro and In Vivo Evaluation of Diclofenac Sodium Loaded Album in Microspheres. Informa Healthcare. 2000; 17(2): 145-155.
97. Uddenfeldt P., Leden I, Rubin B. A. Double-Blind Comparison of Oral Ketoprofen Controlled Release and Indomethacin Suppository in the Treatment of Rheumatoid Arthritis with Special Regard to Morning Stiffness and Pain on Awakening. Informa Healthcare. 1999; 13(3): 127-132.
98. Vergote GJ., Vervaet C, Driesch V, Hoste S, Smedt S, Demeester J, Jain RA, Ruddy S, Remon JP. In-Vivo Evaluation of Matrix Pellets Containing Nanocrystalline Ketoprofen. International Journal of Pharmaceutics. 2006; 240(2): 79-84.
99. Vyas SP., Singh R, Asati RK. Liposomally Encapsulated Diclofenac for Sonophoresis Induced Systemic Delivery. Informa Healthcare. 2004; 12(2): 149-154.
100. Whitmore SE. Delayed Systemic Allergic Reactions to Corticosteroids. Indian Journal of Rheumatology. 2006; 32(4): 193-198.
101. Yocum DE., Allard S. Microemulsion Formulation of Cyclosporine. The Journal of Rheumatology. 2005; 39: 156-164.
102. Yun-Seok R., Jung-Gyo C, Eun-Seok P, Sang-Cheol C. Transdermal Delivery of Ketoprofen using Microemulsions. International Journal of Pharmaceutics. 2006; 228(2):161-170.
103. Zaghloul AA., Vaithiyalingam SR, Faltinek J, Reddy IK, Khan MA. Response Surface Methodology to Obtain Naproxen Controlled Release Tablets from its Microspheres with Eudragit L100-55. Informa Healthcare. 2001; 8(5): 651-662.
104. Zhang Z., Huang, G. Micro- and Nano-Carrier Mediated Intra-Articular Drug Delivery Systems for the Treatment of Osteoarthritis. J. Nanotechnol. 2012; 1(1):112-121.
105. Zong-Zhu P., Mi-Kyung L, Beom-Jin Lee. Colonic Release and Reduced Intestinal Tissue Damage of Coated Tablets Containing Naproxen Inclusion Complex. International Journal of Pharmaceutics. 2008; 350(2): 205-211.
106. Zunig JR., Phillips CL, Shugars D, Lyon JA, Peroutka SJ, Swarbrick J, Charles BM. Analgesic Safety and Efficacy of Diclofenac Sodium Soft Gels on Postoperative Third Molar Extraction Pain. Journal of Oral and Maxillofacial Surgery. 2008; 62(7): 806-815.